Revenue
2013
2014
2015
2016
2017
2022
2023
2024
2025
Tempest Therapeutics, Inc. (TPST)
Price$1.03Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | $295,000 | $653,000 | $277,000 | $0 | $0 | — |
| Gross profit | — | — | — | — | — | — | — | — | −$495,000 | −$4.7M | −$2.0M | $0 | $0 | — |
| Gross margin | — | — | — | — | — | — | — | — | −167.80% | −727.11% | −711.91% | — | — | — |
| Research & development | $12.6M | $28.5M | $17.5M | $22.5M | $17.2M | $14.4M | $27.8M | $14.4M | $14.5M | $21.6M | $18.4M | $21.8M | $15.8M | $6.3M |
| Operating expenses | $26.6M | $42.0M | $29.2M | $34.6M | — | — | — | — | $50.9M | $81.7M | $72.3M | $47.9M | $29.1M | $13.5M |
| Operating income | −$26.6M | −$42.0M | −$29.2M | −$34.6M | −$27.0M | −$19.3M | −$45.4M | −$26.9M | −$84.3M | −$81.0M | −$72.0M | −$47.9M | −$29.1M | −$13.5M |
| Operating margin | — | — | — | — | — | — | — | — | −28,585.08% | −12,406.13% | −25,992.42% | — | — | — |
| EBITDA | −$26.3M | −$41.6M | −$28.8M | −$34.0M | −$26.6M | −$19.0M | −$45.3M | −$26.8M | −$82.7M | −$78.8M | −$70.7M | −$47.5M | −$28.9M | −$13.4M |
| EBITDA margin | — | — | — | — | — | — | — | — | −28,025.76% | −12,063.40% | −25,528.16% | — | — | — |
| Net income | −$26.3M | −$41.8M | −$29.5M | −$35.7M | −$28.3M | −$19.2M | −$44.6M | −$27.2M | −$84.6M | −$82.3M | −$73.2M | −$49.5M | −$29.0M | −$13.5M |
| Net profit margin | — | — | — | — | — | — | — | — | −28,670.51% | −12,597.24% | −26,432.85% | — | — | — |
| Basic EPSper basic share | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | -$1,521.00 | -$8,227.44 | -$150,607.08 | -$1,198.08 | -$1,263.60 | -$1,024.92 | -$842.40 | -$1,090.44 |
| Diluted EPSper diluted share | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | -$1,521.00 | -$8,227.44 | -$150,607.08 | -$1,198.08 | -$1,263.60 | -$1,024.92 | -$842.40 | -$1,090.44 |
Owners
Reported shareholders
≈21.95%of listed shares
Versant Venture Capital VI, L.P. / Versant Ventures IV, LLC / Versant Side Fund IV, L.P. / Versant Vantage II GP, L.P. / Versant Venture Capital IV, L.P. / Versant Ventures VI GP-GP, LLC / Versant Vantage II GP-GP, LLC / Versant Ventures VI GP, L.P. / Versant Vantage II, L.P.3.51M shares · Aug 12, 2024
View holders
| Holder | % owned |
|---|---|
Versant Venture Capital VI, L.P. / Versant Ventures IV, LLC / Versant Side Fund IV, L.P. / Versant Vantage II GP, L.P. / Versant Venture Capital IV, L.P. / Versant Ventures VI GP-GP, LLC / Versant Vantage II GP-GP, LLC / Versant Ventures VI GP, L.P. / Versant Vantage II, L.P. | ≈21.95%3.51M shares |
SABBY MANAGEMENT, LLC | 3.20%511.29K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.46%233.89K shares |
Angel Matthew | ≈1.45%231.48K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.54%86.63K shares |
VANGUARD FIDUCIARY TRUST CO | 0.43%68.91K shares |
Brady Stephen R | ≈0.29%46.38K shares |
BlackRock, Inc. | 0.24%39.07K shares |
Squarepoint Ops LLC | 0.19%30.9K shares |
Trojanowski Justin | ≈0.14%22.17K shares |
NORTHERN TRUST CORP | 0.13%20.14K shares |
CITADEL ADVISORS LLC | 0.12%19.82K shares |
Whiting Samuel | ≈0.06%9.57K shares |
UBS Group AG | 0.04%5.64K shares |
Tower Research Capital LLC (TRC) | 0.02%3.92K shares |
MORGAN STANLEY | 0.01%2.02K shares |
Richey William Drake | ≈0.01%2K shares |
OSAIC HOLDINGS, INC. | <0.01%1.51K shares |
Federation des caisses Desjardins du Quebec | <0.01%292 shares |
JONES FINANCIAL COMPANIES LLLP | <0.01%239 shares |
Percentages use 15.98M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 24, 2026Form 4 | Angel MatthewCEO and President | BuyCommon Stock · indirect | 231.5K | $2.16 | $500.0K | 231.5K |
| Mar 24, 2026Form 4 | Angel MatthewCEO and President | BuySeries B Warrant (right to buy) · derivative · indirect | 231.5K | — | — | 231.5K |
| Mar 24, 2026Form 4 | Angel MatthewCEO and President | BuySeries A Warrant (right to buy) · derivative · indirect | 231.5K | — | — | 231.5K |
| Mar 24, 2026Form 4 | Angel MatthewCEO and President | BuyCommon Stock · indirect | 231.5K | $2.16 | $500.0K | 231.5K |
| Aug 12, 2024Form 4 | Versant Venture Capital VI, L.P. +8TenPercentOwner | SellCommon Stock | 388.0K | $1.10 | $426.8K | 209.9K |